{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:09:24Z","timestamp":1778724564338,"version":"3.51.4"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014895","name":"Southwest Medical University","doi-asserted-by":"publisher","award":["2024LZXNYDJ101"],"award-info":[{"award-number":["2024LZXNYDJ101"]}],"id":[{"id":"10.13039\/501100014895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejphar.2026.178858","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T16:13:56Z","timestamp":1776442436000},"page":"178858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pleiotropic mechanisms and translational trajectory of SGLT2 inhibitors in sepsis-induced cardiomyopathy: Navigating the evidence hierarchy"],"prefix":"10.1016","volume":"1023","author":[{"given":"Xinge","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liuyi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bimin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shurong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"34","key":"10.1016\/j.ejphar.2026.178858_bib1","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1093\/eurheartj\/ehaf340","article-title":"Sepsis-induced cardiomyopathy","volume":"46","author":"Aissaoui","year":"2025","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.ejphar.2026.178858_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4266\/acc.2023.01046","article-title":"Are sodium-glucose co-transporter-2 inhibitors associated with improved outcomes in diabetic patients admitted to intensive care units with septic shock?","volume":"39","author":"Ashcherkin","year":"2024","journal-title":"Acute Crit Care"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178858_bib3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5152\/eurasianjmed.2023.23364","article-title":"Experimental sepsis models: advantages and limitations","volume":"55","author":"Ayd\u0131n","year":"2023","journal-title":"Eurasian J Med"},{"issue":"3","key":"10.1016\/j.ejphar.2026.178858_bib4","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.ejphar.2026.178858_bib5","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1053\/j.jvca.2019.10.017","article-title":"Adrenergic downregulation in critical care: molecular mechanisms and therapeutic evidence","volume":"34","author":"Belletti","year":"2020","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"10.1016\/j.ejphar.2026.178858_bib6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.yjmcc.2014.09.023","article-title":"The mitochondrial permeability transition pore: molecular nature and role as a target in cardioprotection","volume":"78","author":"Bernardi","year":"2015","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"2","key":"10.1016\/j.ejphar.2026.178858_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178858_bib8","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s13054-025-05639-6","article-title":"Plasma proteomics identifies molecular subtypes in sepsis","volume":"29","author":"Bracht","year":"2025","journal-title":"Crit. Care"},{"issue":"2","key":"10.1016\/j.ejphar.2026.178858_bib9","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/toxres\/tfad007","article-title":"Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating AMPK\/SIRT-1\/PGC-1\u03b1-mediated mitochondrial biogenesis","volume":"12","author":"Chen","year":"2023","journal-title":"Toxicol Res (Camb)"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178858_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-022-01480-1","article-title":"Direct cardiac effects of SGLT2 inhibitors","volume":"21","author":"Chen","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"issue":"8","key":"10.1016\/j.ejphar.2026.178858_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.039105","article-title":"Early initiation of sodium-glucose cotransporter 2 inhibitors in acute heart failure: a systematic review and meta-analysis","volume":"14","author":"Cherbi","year":"2025","journal-title":"J. Am. Heart Assoc."},{"issue":"2","key":"10.1016\/j.ejphar.2026.178858_bib12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4093\/dmj.2023.0201","article-title":"Abrupt decline in estimated glomerular filtration rate after initiating sodium-glucose cotransporter 2 inhibitors predicts clinical outcomes: a systematic review and meta-analysis","volume":"48","author":"Chuang","year":"2024","journal-title":"Diabetes Metab. J"},{"issue":"14","key":"10.1016\/j.ejphar.2026.178858_bib13","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1093\/cvr\/cvaa323","article-title":"Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+\/H+ exchanger-1 or lower [Na+]i in the heart","volume":"117","author":"Chung","year":"2021","journal-title":"Cardiovasc. Res."},{"issue":"6","key":"10.1016\/j.ejphar.2026.178858_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/mbo3.70155","article-title":"Glycocalyx and endothelial biomarkers as prognostic indicators in sepsis: a systematic review and meta-analysis","volume":"14","author":"Daniyarova","year":"2025","journal-title":"Microbiologyopen"},{"issue":"1 Suppl. 1","key":"10.1016\/j.ejphar.2026.178858_bib15","first-page":"S321","article-title":"Diabetes care in the hospital: standards of care in Diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.ejphar.2026.178858_bib16","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.ejphar.2026.178858_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.yjmcc.2024.08.003","article-title":"Mechanisms of the septic heart: from inflammatory response to myocardial edema","volume":"195","author":"Fan","year":"2024","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"6","key":"10.1016\/j.ejphar.2026.178858_bib18","doi-asserted-by":"crossref","first-page":"862","DOI":"10.2174\/1874467214666211008142347","article-title":"Dapagliflozin protects H9c2 cells against injury induced by lipopolysaccharide via suppression of CX3CL1\/CX3CR1 axis and NF-\u03baB activity","volume":"15","author":"Faridvand","year":"2022","journal-title":"Curr. Mol. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejphar.2026.178858_bib19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/ehjcvp\/pvaf040","article-title":"Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomized controlled trials","volume":"11","author":"Fedele","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"5","key":"10.1016\/j.ejphar.2026.178858_bib20","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.ejphar.2026.178858_bib21","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1177\/08971900221100205","article-title":"Bioavailability of orally administered drugs in critically ill patients","volume":"36","author":"Forsberg","year":"2023","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.ejphar.2026.178858_bib22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijcard.2022.07.048","article-title":"Empagliflozin inhibits macrophage inflammation through AMPK signaling pathway and plays an anti-atherosclerosis role","volume":"367","author":"Fu","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejphar.2026.178858_bib23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.yjmcc.2023.05.003","article-title":"NLRP3 inflammasome-driven IL-1\u03b2 and IL-18 contribute to lipopolysaccharide-induced septic cardiomyopathy","volume":"180","author":"Fujimura","year":"2023","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178858_bib24","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1186\/s13054-025-05781-1","article-title":"Misclassification of sepsis using ICD-10 codes A00-B99 in the study","volume":"29","author":"Gan","year":"2025","journal-title":"Crit. Care"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178858_bib25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00134-024-07704-0","article-title":"How to manage sodium-glucose cotransporter-2 inhibitors in the critically ill patient?","volume":"51","author":"Garcia","year":"2025","journal-title":"Intensive Care Med."},{"issue":"24","key":"10.1016\/j.ejphar.2026.178858_bib26","doi-asserted-by":"crossref","DOI":"10.1172\/JCI176708","article-title":"SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts","volume":"134","author":"Goedeke","year":"2024","journal-title":"J. Clin. Investig."},{"issue":"11","key":"10.1016\/j.ejphar.2026.178858_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115437","article-title":"Low-dose empagliflozin improves systolic heart function after myocardial infarction in rats: regulation of MMP9, NHE1, and SERCA2a","volume":"22","author":"Goerg","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178858_bib28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13613-025-01561-w","article-title":"Sepsis-induced myocardial dysfunction diagnosed with strain versus non-strain echocardiography parameters: incidence, evolution and association with prognosis","volume":"15","author":"Gonzalez","year":"2025","journal-title":"Ann. Intensive Care"},{"key":"10.1016\/j.ejphar.2026.178858_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175930","article-title":"Dapagliflozin ameliorates sepsis-induced heart injury by inhibiting cardiomyocyte apoptosis and electrical remodeling through the PI3K\/Akt pathway","volume":"955","author":"Han","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.ejphar.2026.178858_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15112598","article-title":"Oral drug absorption and drug disposition in critically ill cardiac patients","volume":"15","author":"Harnisch","year":"2023","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.ejphar.2026.178858_bib31","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1177\/08850666231180526","article-title":"Prevalence and prognosis of sepsis-induced cardiomyopathy: a systematic review and meta-analysis","volume":"38","author":"Hasegawa","year":"2023","journal-title":"J. Intensive Care Med."},{"issue":"4","key":"10.1016\/j.ejphar.2026.178858_bib32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2217\/bmm-2023-0605","article-title":"Meta-analysis of initial natriuretic peptides in the setting of sepsis-induced myocardial dysfunction","volume":"18","author":"He","year":"2024","journal-title":"Biomarkers Med."},{"issue":"4","key":"10.1016\/j.ejphar.2026.178858_bib33","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/cvr\/cvaa143","article-title":"Ketones can become the major fuel source for the heart but do not increase cardiac efficiency","volume":"117","author":"Ho","year":"2021","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178858_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/SHK.0000000000000261","article-title":"Dysregulation of intracellular calcium transporters in animal models of sepsis-induced cardiomyopathy","volume":"43","author":"Hobai","year":"2015","journal-title":"Shock"},{"issue":"6","key":"10.1016\/j.ejphar.2026.178858_bib35","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41569-020-00492-2","article-title":"Pathophysiology of sepsis-induced cardiomyopathy","volume":"18","author":"Hollenberg","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"issue":"4","key":"10.1016\/j.ejphar.2026.178858_bib36","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10863-024-10020-3","article-title":"Dapagliflozin attenuates LPS-induced myocardial injury by reducing ferroptosis","volume":"56","author":"Hu","year":"2024","journal-title":"J. Bioenerg. Biomembr."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178858_bib37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13613-024-01301-6","article-title":"Managing sepsis and septic shock in an endothelial glycocalyx-friendly way: from the viewpoint of surviving sepsis campaign guidelines","volume":"14","author":"Iba","year":"2024","journal-title":"Ann. Intensive Care"},{"issue":"3","key":"10.1016\/j.ejphar.2026.178858_bib38","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/SHK.0000000000000473","article-title":"The endothelium in sepsis","volume":"45","author":"Ince","year":"2016","journal-title":"Shock"},{"issue":"7","key":"10.1016\/j.ejphar.2026.178858_bib39","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s43587-024-00642-y","article-title":"SGLT2 inhibition eliminates senescent cells and alleviates pathological aging","volume":"4","author":"Katsuumi","year":"2024","journal-title":"Nat. Aging"},{"issue":"12","key":"10.1016\/j.ejphar.2026.178858_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11120846","article-title":"Cardiac metabolism in sepsis","volume":"11","author":"Kawaguchi","year":"2021","journal-title":"Metabolites"},{"issue":"4s","key":"10.1016\/j.ejphar.2026.178858_bib41","first-page":"S117","article-title":"Clinical practice guideline for the evaluation and management of chronic kidney disease. 2024","volume":"105","year":"2024","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.ejphar.2026.178858_bib42","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","article-title":"Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation","volume":"117","author":"Kolijn","year":"2021","journal-title":"Cardiovasc. Res."},{"issue":"48","key":"10.1016\/j.ejphar.2026.178858_bib43","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1093\/eurheartj\/ehab420","article-title":"Effects of canagliflozin on human myocardial redox signalling: clinical implications","volume":"42","author":"Kondo","year":"2021","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.ejphar.2026.178858_bib44","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S2213-8587(21)00180-7","article-title":"Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Kosiborod","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"10.1016\/j.ejphar.2026.178858_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25094710","article-title":"Current perspectives of mitochondria in sepsis-induced cardiomyopathy","volume":"25","author":"Kuroshima","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ejphar.2026.178858_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/biom15020286","article-title":"Integrated omics insights into dapagliflozin effects in sepsis-induced cardiomyopathy","volume":"15","author":"Lai","year":"2025","journal-title":"Biomolecules"},{"issue":"12","key":"10.1016\/j.ejphar.2026.178858_bib47","doi-asserted-by":"crossref","first-page":"e2013","DOI":"10.1016\/S2214-109X(25)00356-0","article-title":"Global, regional, and national sepsis incidence and mortality, 1990-2021: a systematic analysis","volume":"13","year":"2025","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.ejphar.2026.178858_bib48","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejphar.2026.178858_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114674","article-title":"Dapagliflozin attenuates arrhythmic vulnerabilities by regulating connexin43 expression via the AMPK pathway in post-infarcted rat hearts","volume":"192","author":"Lee","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178858_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101215","article-title":"STING-IRF3 contributes to lipopolysaccharide-induced cardiac dysfunction, inflammation, apoptosis and pyroptosis by activating NLRP3","volume":"24","author":"Li","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejphar.2026.178858_bib51","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.freeradbiomed.2020.08.009","article-title":"Ferritinophagy-mediated ferroptosis is involved in sepsis-induced cardiac injury","volume":"160","author":"Li","year":"2020","journal-title":"Free Radic. Biol. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2026.178858_bib52","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018298","article-title":"Direct cardiac actions of the sodium glucose Co-Transporter 2 inhibitor empagliflozin improve myocardial oxidative phosphorylation and attenuate pressure-overload heart failure","volume":"10","author":"Li","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ejphar.2026.178858_bib53","article-title":"Direct cardiac actions of sodium-glucose cotransporter 2 inhibition improve mitochondrial function and attenuate oxidative stress in pressure overload-induced heart failure","volume":"9","author":"Li","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2026.178858_bib54","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00011-024-01881-w","article-title":"PLD2 deletion ameliorates sepsis-induced cardiomyopathy by suppressing cardiomyocyte pyroptosis via the NLRP3\/caspase 1\/GSDMD pathway","volume":"73","author":"Li","year":"2024","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.ejphar.2026.178858_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2019.110642","article-title":"Empagliflozin attenuates ischemia and reperfusion injury through LKB1\/AMPK signaling pathway","volume":"501","author":"Lu","year":"2020","journal-title":"Mol. Cell. Endocrinol."},{"issue":"21","key":"10.1016\/j.ejphar.2026.178858_bib56","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178858_bib57","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13613-021-00937-y","article-title":"Long-term cardiovascular complications following sepsis: is senescence the missing link?","volume":"11","author":"Merdji","year":"2021","journal-title":"Ann. Intensive Care"},{"issue":"12","key":"10.1016\/j.ejphar.2026.178858_bib58","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1038\/s41591-025-03956-5","article-title":"A consensus immune dysregulation framework for sepsis and critical illnesses","volume":"31","author":"Moore","year":"2025","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178858_bib59","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s41420-022-01287-9","article-title":"PKM2 deficiency exacerbates gram-negative sepsis-induced cardiomyopathy via disrupting cardiac calcium homeostasis","volume":"8","author":"Ni","year":"2022","journal-title":"Cell Death Discov."},{"issue":"23","key":"10.1016\/j.ejphar.2026.178858_bib60","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1016\/j.jacc.2020.10.005","article-title":"Effect of empagliflozin on hemodynamics in patients with heart failure and reduced ejection fraction","volume":"76","author":"Omar","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"15","key":"10.1016\/j.ejphar.2026.178858_bib61","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejphar.2026.178858_bib62","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ejphar.2026.178858_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13112643","article-title":"Sepsis-induced cardiomyopathy and cardiac arrhythmias: pathophysiology and implications for novel therapeutic approaches","volume":"13","author":"Pamporis","year":"2025","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.ejphar.2026.178858_bib64","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.4161\/auto.26502","article-title":"Protective role of PARK2\/Parkin in sepsis-induced cardiac contractile and mitochondrial dysfunction","volume":"9","author":"Piquereau","year":"2013","journal-title":"Autophagy"},{"issue":"5","key":"10.1016\/j.ejphar.2026.178858_bib65","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/cvr\/cvae047","article-title":"SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits","volume":"120","author":"Preda","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2026.178858_bib66","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jcrc.2016.06.027","article-title":"Plasma syndecan-1 levels identify a cohort of patients with severe sepsis at high risk for intubation after large-volume intravenous fluid resuscitation","volume":"36","author":"Puskarich","year":"2016","journal-title":"J. Crit. Care"},{"issue":"18","key":"10.1016\/j.ejphar.2026.178858_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/cells14181452","article-title":"Empagliflozin preserves cardiomyocyte structural homeostasis via the stabilization of the integrin \u03b15-Desmocollin-2 adhesion axis in sepsis-induced cardiomyopathy","volume":"14","author":"Qiao","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2026.178858_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.973129","article-title":"Risk of hypovolemia associated with sodium-glucose cotransporter-2 inhibitors treatment: a meta-analysis of randomized controlled trials","volume":"9","author":"Rong","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2026.178858_bib69","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.chest.2025.08.013","article-title":"Sepsis-induced cardiomyopathy: mechanism, prevalence, assessment, prognosis, and management","volume":"168","author":"Sato","year":"2025","journal-title":"Chest"},{"issue":"20","key":"10.1016\/j.ejphar.2026.178858_bib70","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.2019.5791","article-title":"Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis","volume":"321","author":"Seymour","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ejphar.2026.178858_bib71","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.18632\/aging.102691","article-title":"SRV2 promotes mitochondrial fission and Mst1-Drp1 signaling in LPS-Induced septic cardiomyopathy","volume":"12","author":"Shang","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"6116","key":"10.1016\/j.ejphar.2026.178858_bib72","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.1227166","article-title":"Suppression of oxidative stress by \u03b2-hydroxybutyrate, an endogenous histone deacetylase inhibitor","volume":"339","author":"Shimazu","year":"2013","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.ejphar.2026.178858_bib73","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2026.178858_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109825","article-title":"The SGLT2 inhibitor empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2\/ROS\/NLRP3\/Caspase-1-dependent IL-1\u03b2 and IL-18 secretion","volume":"77","author":"Sukhanov","year":"2021","journal-title":"Cell. Signal."},{"issue":"8","key":"10.1016\/j.ejphar.2026.178858_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e19152","article-title":"Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes","volume":"9","author":"Tai","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.ejphar.2026.178858_bib76","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on water and sodium metabolism","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178858_bib77","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1038\/s41467-022-35242-0","article-title":"TRPC channels blockade abolishes endotoxemic cardiac dysfunction by hampering intracellular inflammation and Ca(2+) leakage","volume":"13","author":"Tang","year":"2022","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.ejphar.2026.178858_bib78","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2024.10510","article-title":"Dapagliflozin for critically ill patients with acute organ dysfunction: the DEFENDER randomized clinical trial","volume":"332","author":"Tavares","year":"2024","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ejphar.2026.178858_bib79","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.202401-0101CP","article-title":"The rise of adaptive platform trials in critical care","volume":"209","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.ejphar.2026.178858_bib80","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/cvr\/cvv008","article-title":"TNF-\u03b1 down-regulates sarcoplasmic reticulum Ca2+ ATPase expression and leads to left ventricular diastolic dysfunction through binding of NF-\u03baB to promoter response element","volume":"105","author":"Tsai","year":"2015","journal-title":"Cardiovasc. Res."},{"issue":"7","key":"10.1016\/j.ejphar.2026.178858_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/genes14071366","article-title":"Comparative analysis of whole transcriptome profiles in septic cardiomyopathy: insights from CLP- and LPS-induced mouse models","volume":"14","author":"Ullah","year":"2023","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178858_bib82","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1186\/s13054-025-05684-1","article-title":"Predictive enrichment using biomarkers in studies of critically-ill patients with sepsis: a systematic review","volume":"29","author":"Van Nynatten","year":"2025","journal-title":"Crit. Care"},{"issue":"4","key":"10.1016\/j.ejphar.2026.178858_bib83","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1161\/CIRCULATIONAHA.113.003183","article-title":"G\u03b2\u03b3-independent recruitment of G-protein coupled receptor kinase 2 drives tumor necrosis factor \u03b1-induced cardiac \u03b2-adrenergic receptor dysfunction","volume":"128","author":"Vasudevan","year":"2013","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ejphar.2026.178858_bib84","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat. Med."},{"issue":"14","key":"10.1016\/j.ejphar.2026.178858_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18147598","article-title":"Heart metabolism in sepsis-induced cardiomyopathy-unusual metabolic dysfunction of the heart","volume":"18","author":"Wasyluk","year":"2021","journal-title":"Int. J. Environ. Res. Publ. Health"},{"issue":"1","key":"10.1016\/j.ejphar.2026.178858_bib86","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12933-024-02520-8","article-title":"SGLT2 inhibitor downregulates ANGPTL4 to mitigate pathological aging of cardiomyocytes induced by type 2 diabetes","volume":"23","author":"Wen","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178858_bib87","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1186\/s13054-025-05685-0","article-title":"Association between SGLT2 inhibitor use and risk of sepsis-induced cardiomyopathy in patients with type 2 diabetes: a propensity-matched cohort study","volume":"29","author":"Wu","year":"2025","journal-title":"Crit. Care"},{"key":"10.1016\/j.ejphar.2026.178858_bib88","doi-asserted-by":"crossref","DOI":"10.1097\/SHK.0000000000002683","article-title":"Macrophages in septic cardiomyopathy: heterogeneity, function, and therapy","author":"Wu","year":"2025","journal-title":"Shock"},{"issue":"2","key":"10.1016\/j.ejphar.2026.178858_bib89","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.molcel.2016.03.036","article-title":"Metabolic regulation of gene expression by histone lysine \u03b2-Hydroxybutyrylation","volume":"62","author":"Xie","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejphar.2026.178858_bib90","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.2147\/IDR.S505836","article-title":"Validation of senescence of the role of ATM\/P53 pathway in myocardial senescence in mice with sepsis","volume":"18","author":"Yan","year":"2025","journal-title":"Infect. Drug Resist."},{"issue":"3","key":"10.1016\/j.ejphar.2026.178858_bib91","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1074\/jbc.M117.812289","article-title":"Toll-like receptor 4-induced ryanodine receptor 2 oxidation and sarcoplasmic reticulum Ca(2+) leakage promote cardiac contractile dysfunction in sepsis","volume":"293","author":"Yang","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.ejphar.2026.178858_bib92","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease","volume":"21","author":"Youm","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2026.178858_bib93","article-title":"Sodium-glucose Co-transporter-2 inhibitor of dapagliflozin attenuates myocardial ischemia\/reperfusion injury by limiting NLRP3 inflammasome activation and modulating autophagy","volume":"8","author":"Yu","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178858_bib94","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s13054-025-05534-0","article-title":"Effects of dapagliflozin on urinary output, fluid balance, and biochemistry in critically ill patients: a post-hoc secondary analysis of the DEFENDER trial","volume":"29","author":"Zampieri","year":"2025","journal-title":"Crit. Care"},{"key":"10.1016\/j.ejphar.2026.178858_bib95","article-title":"Advances in neutrophil extracellular traps and ferroptosis in sepsis-induced cardiomyopathy","volume":"16","author":"Zeng","year":"2025","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.ejphar.2026.178858_bib96","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2022.12773","article-title":"Cardiomyocyte death in sepsis: mechanisms and regulation","volume":"26","author":"Zhang","year":"2022","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejphar.2026.178858_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177438","article-title":"Inhibition of Piezo1 ameliorates septic cardiomyopathy by blocking calcium-dependent PANoptosis","volume":"996","author":"Zhang","year":"2025","journal-title":"Eur. J. Pharmacol."},{"issue":"Pt A","key":"10.1016\/j.ejphar.2026.178858_bib98","article-title":"Dapagliflozin attenuates the vulnerability to atrial fibrillation in rats with lipopolysaccharide-induced myocardial injury","volume":"125","author":"Zhao","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"10.1016\/j.ejphar.2026.178858_bib99","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.1014","article-title":"Cardiac troponin as a prognosticator of mortality in patients with sepsis: a systematic review and meta-analysis","volume":"11","author":"Zheng","year":"2023","journal-title":"Immun. Inflamm. Dis."},{"issue":"1","key":"10.1016\/j.ejphar.2026.178858_bib100","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13613-024-01393-0","article-title":"Angiopoietin-2 as a prognostic biomarker in septic adult patients: a systemic review and meta-analysis","volume":"14","author":"Zhuo","year":"2024","journal-title":"Ann. Intensive Care"},{"issue":"22","key":"10.1016\/j.ejphar.2026.178858_bib101","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926003407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926003407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:35:38Z","timestamp":1778722538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926003407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":101,"alternative-id":["S0014299926003407"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178858","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pleiotropic mechanisms and translational trajectory of SGLT2 inhibitors in sepsis-induced cardiomyopathy: Navigating the evidence hierarchy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178858","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178858"}}